Pulse Explorar nav.journalClub Debates Tendencias Investigadores Revistas

Join discussions, follow papers, and never miss your next session.

Download on theApp Store

Inicio Explorar nav.journalClub Tendencias

⌘+K

April 30, 2014Open Access

Ver artículo completo

Overall Survival in Renal-Cell Carcinoma with Pazopanib versus Sunitinib

Robert J. MotzerUniversité Claude Bernard Lyon 1 THThomas E. HutsonTexas Tech University LMLauren McCannWollongong Hospital

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

Survival results are now mature for a noninferiority trial comparing pazopanib with sunitinib in renal-cell carcinoma. Median survival was 42.5 months with pazopanib and 43.6 months with sunitinib, a difference that wasnot significant.

Preguntar a la IA

Me gusta

Guardar

Compartir

Ver artículo completo

Preguntar a la IA

Me gusta

Guardar

Compartir

Ver artículo completo

Cite This Study

Motzer et al. (Wed,) studied this question.

synapsesocial.com/papers/6a59ae9bae8f35aab9bea61e https://doi.org/https://doi.org/10.1056/nejmc1400731

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Interferon-Alfa as a Comparative Treatment for Clinical Trials of New Therapies Against Advanced Renal Cell Carcinoma2002 · 609 citations
2Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma2013 · 1,924 citations
3Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma2007 · 5,767 citations
4Evaluation of Chemotherapeutic Agents.1950 · 1,137 citations
5New Guidelines to Evaluate the Response to Treatment in Solid Tumors2000 · 15,737 citations

Supervivencia global en carcinoma de células renales con pazopanib frente a sunitinib | Synapse